Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
ANIK
$21.50
+1.56%
ANIK · Anika Therapeutics, Inc.
$21.50
+0.33 (+1.56%)
At close · Aug 14
View the 10-Q filed Jul 29, 2026
Customer concentration
— top customer 53% of revenue
One customer — 53% of revenue (the three months ended June 30, 2026)
“Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
One customer — 50% of revenue (the six months ended June 30, 2026)
“Revenue from the Company’s sole significant customer, Johnson & Johnson MedTech (“J&J MedTech”), part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
Market Cap
$287.73M
Shares
13.38M
All earnings calls
Earnings call · FY2019 Q4
Anika Therapeutics, Inc. Q4 FY2019 Earnings Call
Anika Therapeutics, Inc. Q4 FY2019 Earnings Call
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$29.77M
+10.4% YoY
Diluted EPS
$0.28
-48.1% YoY
Gross margin
70.9%
-3.1 pp YoY
Net income
$4.05M
-47.5% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Feb 20, 2020 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 6, 2020 · complete as-filed document